Oral Vaccine Market Report 2026

Oral Vaccine Market Overview

• Oral Vaccine market size has reached to $3.95 billion in 2025 • Expected to grow to $6.29 billion in 2030 at a compound annual growth rate (CAGR) of 9.7% • Growth Driver: Rise In Infectious Diseases Fueling The Growth Of The Market Due To Increasing Global Travel And Pathogen Transmission • Market Trend: Advancement In Oral Vaccine Technology Driving Innovation Through Needle-Free And Scalable Immunization Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Vaccine Market?

An oral vaccine is a type of immunization administered through the mouth, typically in liquid, tablet, or capsule form, to stimulate an immune response against specific pathogens. It works by introducing antigens into the body via the gastrointestinal tract, where the immune system recognizes and responds to them. The main types of oral vaccines include live attenuated vaccines, inactivated vaccines, subunit vaccines, and others. Live attenuated vaccines refer to vaccines containing weakened forms of pathogens used to stimulate a strong immune response without causing disease. It is applied for polio, tuberculosis, rabies, influenza, cholera, and others by several end-users, including hospitals, clinics, government organizations, and others.

What Is The Oral Vaccine Market Growth Forecast?

The oral vaccine market size is expected to see strong growth in the next few years. It will grow to $6.29 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to launch of novel oral vaccines (dna, rna, vlp), expansion of global immunization programs, integration of digital health and monitoring tools, rising investment in vaccine research and development, increased focus on adult and travel vaccinations. Major trends in the forecast period include rising adoption of oral vaccines for pediatric immunization, increasing focus on preventive healthcare and mass vaccination programs, development of live attenuated and subunit oral vaccines, expansion of government-funded immunization campaigns, integration of cold chain and logistics innovations for vaccine distribution.

What Is The Driver Of The Oral Vaccine Market?

The rising prevalence of infectious diseases is expected to propel the growth of the oral vaccine market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted between individuals or through the environment. Infectious diseases are rising due to increasing global travel, which enables the rapid movement of people and pathogens across borders, accelerating the spread of infections worldwide. Oral vaccines are beneficial for infectious diseases as they stimulate mucosal immunity in the gut, which is a primary entry point for many pathogens, thereby offering effective protection at the site of infection. For instance, in May 2025, according to the Health Security Agency, a UK-based government department, in England, the number of reported tuberculosis (TB) cases in 2023 showed an 11.0% increase compared to 2022. Therefore, the rising prevalence of infectious diseases is driving the growth of the oral vaccine industry.

Key Players In The Global Oral Vaccine Market

Major companies operating in the oral vaccine market are Panacea Biotec Ltd., Zydus Lifesciences, Serum Institute of India Pvt. Ltd., Bharat Biotech Ltd., Haffkine Biopharmaceutical Co. Ltd., Medigen Vaccine Biologics Corp., BlueWillow Biologics Inc.

Global Oral Vaccine Market Trends and Insights

Major companies operating in the oral vaccine market are focusing on developing innovative products, such as second-generation oral pill vaccines, to enhance immune response and ease of administration. A second-generation pill-based oral vaccine is designed to improve immunogenicity, broaden protection, and streamline mass immunization without the need for needles or cold-chain storage. For instance, in March 2025, Vaxart Inc., a U.S.-based biotechnology company, announced the initiation of a Phase 1 clinical trial for its second-generation oral norovirus vaccine delivered in pill formulation. This trial will evaluate improved immune responses and safety features of the updated constructs, aiming to address the ongoing global need for accessible and effective norovirus immunization. The pill format removes barriers associated with injectable vaccines and supports rapid, large-scale distribution, particularly during outbreaks.

What Are Latest Mergers And Acquisitions In The Oral Vaccine Market?

In March 2024, the International Vaccine Institute (IVI), a South Korea-based nonprofit organization dedicated to global vaccine development, partnered with Biological E. Limited to manufacture a simplified oral cholera vaccine (OCV-S) for India and international markets. As a result of the partnership, IVI will contribute its technical knowledge and support the clinical development and regulatory approval processes to enable the production of cost-effective oral cholera vaccines. The transfer of technology is scheduled for completion by 2025 to help address the rising global need due to escalating cholera outbreaks. Biological E. Limited is an India-based manufacturer of oral vaccines.

What Defines the Oral Vaccine Market?

The oral vaccine market consists of sales of oral booster doses, oral vaccine delivery systems, vaccine stabilizers, and mucosal immunology research tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Vaccine Market Report 2026?

The oral vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.